Home > Insider Trading > Filing (0001209191-22-056427)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1812364	Relay Therapeutics Inc.	RLAY	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816210	Sanjiv Patel	C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-11-08	14,000	$4.12	268,554	No	4	M	Direct
Common Stock	Disposition	2022-11-08	14,000	$20.18	254,554	No	4	S	Direct
Common Stock	Acquisiton	2022-11-10	18,175	$4.12	272,729	No	4	M	Direct
Common Stock	Disposition	2022-11-10	18,175	$20.00	254,554	No	4	S	Direct
Common Stock	Acquisiton	2022-11-10	9,825	$5.04	264,379	No	4	M	Direct
Common Stock	Disposition	2022-11-10	9,825	$20.00	254,554	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-11-08	14,000	$0.00	14,000	$4.12
Common Stock	Stock Option (Right to Buy)	Disposition	2022-11-10	18,175	$0.00	18,175	$4.12
Common Stock	Stock Option (Right to Buy)	Disposition	2022-11-10	9,825	$0.00	9,825	$5.04

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,175	2028-03-22	No	4	M	Direct
0	2028-03-22	No	4	M	Direct
694,779	2029-04-22	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	674,548	Indirect	By The Patel Family Irrevocable Trust of 2019
Common Stock	432,801	Indirect	By The SSP Irrevocable Trust of 2020

Footnotes

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022.
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date.
The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date.